| 15.5 0.1 (0.65%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.54 | 1-year : | 22.82 |
| Resists | First : | 16.72 | Second : | 19.54 |
| Pivot price | 14.9  |
|||
| Supports | First : | 14.5 |
Second : | 13.13 |
| MAs | MA(5) : | 15.47 |
MA(20) : | 14.97 |
| MA(100) : | 14.24 |
MA(250) : | 14.37 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 66.6  |
D(3) : | 69.7 |
| RSI | RSI(14): 55.8 |
|||
| 52-week | High : | 30.95 | Low : | 6.65 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IMNM ] has closed below upper band by 27.5%. Bollinger Bands are 32.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.69 - 15.77 | 15.77 - 15.84 |
| Low: | 14.75 - 14.83 | 14.83 - 14.91 |
| Close: | 15.37 - 15.5 | 15.5 - 15.63 |
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Wed, 18 Sep 2024
Bank of New York Mellon Corp Invests $1.82 Million in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Tue, 17 Sep 2024
Immunome (NASDAQ:IMNM) Shares Down 3.3% - MarketBeat
Tue, 17 Sep 2024
Sofinnova Investments Inc. Has $7.93 Million Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Mon, 12 Aug 2024
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 4.304e+007 (%) |
| Held by Institutions | 17.3 (%) |
| Shares Short | 13,780 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.156e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 425.4 % |
| Return on Equity (ttm) | -26.9 % |
| Qtrly Rev. Growth | 1.078e+007 % |
| Gross Profit (p.s.) | -25 |
| Sales Per Share | -112.12 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -7.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -61 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.14 |
| Price to Cash Flow | 6.52 |
| Dividend | 0 |
| Forward Dividend | 1.329e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|